Abstract
Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Current Pharmaceutical Design
Title: P53 and Beta-Catenin in Colorectal Cancer Progression
Volume: 9 Issue: 24
Author(s): Anna Maria Valentini, Michele Pirrelli, Letizia Renna, Raffaele Armentano and Maria Lucia Caruso
Affiliation:
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Abstract: Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Export Options
About this article
Cite this article as:
Valentini Maria Anna, Pirrelli Michele, Renna Letizia, Armentano Raffaele and Caruso Lucia Maria, P53 and Beta-Catenin in Colorectal Cancer Progression, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454216
DOI https://dx.doi.org/10.2174/1381612033454216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug
Current Protein & Peptide Science Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Immunotherapy of Melanoma
Current Molecular Pharmacology Glycosite Analysis in Glycoproteomics by Mass Spectrometry
Current Proteomics Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry